Can
the use of NSAIDs (non-steroidal anti-inflammatory drugs) help to reduce
proliferation rates in some lymphomas and be utilized safely to help
control the disease? We do not have the answer.
DISCLAIMER: First,
NSAIDs are prescription
medications that requires a doctor's supervision.
Second, it has not been proven that
NSAIDs can inhibit or regress lymphomas.
Finally, be aware that chronic doses of NSAIDs may cause bleeding as
well as renal and hepatic problems.
Basis for the hypothesis:
Weaknesses of hypothesis:
 |
Malignant cells are adaptable.
|
|
The activity of NSAIDS may be too subtle to influence disease
progression.
|
Abstracts
NOTE: These are complex issues and concepts. The abstracts that
follow are not proof, but a starting point of investigation.
|
Lymphoma-specific: Celecoxib activates a novel mitochondrial apoptosis
signaling pathway.
FASEB J. 2003 Aug;17(11):1547-9. Epub 2003 Jun 17. PMID:
12824303
|
NO-NSAIDS - Nitrogen Oxide releasing NSAIDS may prove safer and are
potentially more potent.
|
NO-releasing NSAIDs are caspase inhibitors. Trends Immunol. 2001
May;22(5):232-5. Review. PMID:
11323270
|
|
IL-1 beta converting enzyme is a target for nitric oxide-releasing
aspirin: new insights in the antiinflammatory mechanism of nitric
oxide-releasing nonsteroidal antiinflammatory drugs. J Immunol. 2000
Nov 1;165(9):5245-54. PMID:
11046058
|
NF-KB
|
Therapeutic potential of inhibition of the NF- B
pathway in the treatment of inflammation and cancer
- J Clin Invest, January 2001 - jci.org
|
|
Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does
not involve nuclear factor kappa B activation.
Semin Oncol. 2003 Apr;30(2):161-4. PMID:
12720128
|
IL-6
Other
|
